


DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30TH JUNE, 2011

(Rs.in Lakhs)

		STAND ALONE		
	Particulars	Quarter ended 30.06.2011	Quarter ended 30.06.2010	Year Ended 31.03.2011
		Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)
1	Net Sales/Income from operations (Net of Excise Duty)	35855	26254	130544
	Other Operating Income	626	683	1247
	Total Income:	36481	26937	131791
2	<u>Expenditure:</u>			
	a. (Increase)/decrease in stock in trade and work in progress	(3626)	(1424)	3452
	b. Consumption of Raw Material	17908	11578	48668
	c. Purchase of Traded Goods	0	0	0
	d. Employees Cost	2447	1737	8049
	e. Depreciation	1400	1311	5335
	f. Other Expenditure			
	- Manufacturing Expenses	2994	2124	10207
	- Other expenses	3358	2671	10722
	g. Total	24481	17997	86433
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	12000	8940	45358
4	Other Income	1015	490	2613
5	Profit before Interest & Exceptional Items (3+4)	13015	9430	47971
6	Interest	22	22	66
7	<u>Profit after Interest but before Exceptional items (5-6)</u>	<u>12993</u>	<u>9408</u>	<u>47905</u>
8	Exceptional items	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	<u>12993</u>	<u>9408</u>	<u>47905</u>
10	Tax Expense			
	- Current Tax	2465	719	3920
	- MAT Credit Utilisation/Entitlements	260	(5)	128
	- Deferred Tax	9	65	300
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	<u>10259</u>	<u>8629</u>	<u>43557</u>
12	Extra-ordinary items	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	10259	8629	43557




14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2653	2643	2652
15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year			180153
16	Earnings per Share:			
a)	Basic Earnings Per Share before extra-ordinary items Rs.	7.74	6.53	32.90
	Diluted Earnings Per Share before extra-ordinary items Rs.	7.73	6.52	32.88
b)	Basic Earnings Per Share after extra-ordinary items Rs.	7.74	6.53	32.90
	Diluted Earnings Per Share after extra-ordinary items Rs.	7.73	6.52	32.88
17	Public shareholding - No. of shares - Percentage of shareholding	63427130 47.82%	62959045 47.64%	63372210 47.79%
18	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil 69222900 100% 52.18%	Nil 69185100 100% 52.36%	Nil 69222900 100% 52.21%

NOTES:

1. The above results for the quarter ended 30th June 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 6th August, 2011 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Figures for the previous year/period have been regrouped or recasted, wherever necessary.
5. During the current quarter, the company has allotted 54,920 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. The "DSN SEZ Unit" at Visakhapatnam has commenced commercial operations from 1st June, 2011.
7. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2011:
Opening: Nil, Received during the Quarter: 4, Resolved: 4, Closing: Nil

Place: Hyderabad
Date: 6th August, 2011



for Divi's Laboratories Limited

Dr. Murali K. Divi
Chairman & Managing Director

DIVI'S LABORATORIES LIMITED

Hyderabad

PRESS RELEASE dated 06th August, 2011

Divi's Labs earns a PBT of Rs. 130 crores for Q1 of FY12

Divi's Laboratories has earned a Profit before Tax (PBT) of Rs.130 crores on a total income of Rs. 365 crores for the 1st quarter of the year 2011-12 on a Standalone basis. PBT for the corresponding quarter of the last year was Rs.94 crores on a total income of Rs.269 crores. While Income for the Quarter grew by 36%, the PBT grew by 38%.

Profit after Tax (PAT) for the current quarter amounted to Rs.103 crores. The company made a tax provision of Rs.27 crores for the quarter as the company's EOU Unit has now come under regular tax provisions and the first SEZ Unit is eligible for 50% tax exemption. The company had a PAT of Rs. 86 crores during the corresponding quarter of last year.

The new DSN SEZ Unit at Visakhapatnam has commenced commercial operations from 1st June 2011.

